HER3 intracellular domains play a crucial role in HER3/HER2 dimerization and activation of downstream signaling pathways

Protein and Cell

Volumn 3, Issue 10, 2012, Pages 781-789

  Choi, Byung Kwon ^a   Cai, Xiumei ^a,b   Yuan, Bin ^a,c   Huang, Zhao ^a   Fan, Xuejun ^a   Deng, Hui ^a   Zhang, Ningyan ^a   An, Zhiqiang ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b FUDAN UNIVERSITY   (China)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

cell migration; cell proliferation; HER2; HER3; MAPK ERK1 2; PI3K AKT

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NEU DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CHIMERA; CHO CELL; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; CELL MOTION; CHEMICAL STRUCTURE; CHEMISTRY; CRICETULUS; ENZYMOLOGY; GENETICS; HAMSTER; HUMAN; INTRACELLULAR SPACE; METABOLISM; MOLECULAR GENETICS; PROTEIN MULTIMERIZATION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTRACELLULAR SPACE; MAP KINASE SIGNALING SYSTEM; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 84877904390     PISSN: 1674800X     EISSN: 16748018     Source Type: Journal    
DOI: 10.1007/s13238-012-2065-y     Document Type: Article

References (23)

1. Amin, D. N., Campbell, M. R., and Moasser, M. M. (2010a). The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol 21, 944-950.
2. Amin, D. N., Sergina, N., Ahuja, D., McMahon, M., Blair, J. A., Wang, D., Hann, B., Koch, K. M., Shokat, K. M., and Moasser, M. M. (2010b). Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med 2, 16ra17.
3. Baselga, J., and Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9, 463-475.
4. Berger, M. B., Mendrola, J. M., and Lemmon, M. A. (2004). ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 569, 332-336.
5. Campbell, M. R., Amin, D., and Moasser, M. M. (2010). HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res 16, 1373-1383.
6. Chan, S. D., Antoniucci, D. M., Fok, K. S., Alajoki, M. L., Harkins, R. N., Thompson, S. A., and Wada, H. G. (1995). Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. J Biol Chem 270, 22608-22613.
7. Choi, B.-K., Fan, X., Deng, H., Zhang, N. and An, Z. (2012), ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells. Cancer Medicine. doi: 10. 1002/cam4. 10.
8. Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C. M., Zhao, X., Christensen, J., et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043.
9. Huang, Z., Brdlik, C., Jin, P., and Shepard, H. M. (2009). A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther 9, 97-110.
10. Jura, N., Shan, Y., Cao, X., Shaw, D. E., and Kuriyan, J. (2009a). Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc Natl Acad Sci U S A 106, 21608-21613.
11. Jura, N., Endres, N. F., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., and Kuriyan, J. (2009b). Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137, 1293-1307.
12. Kong, A., Calleja, V., Leboucher, P., Harris, A., Parker, P. J., and Larijani, B. (2008). HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One 3, e2881.
13. Krug, A. W., Schuster, C., Gassner, B., Freudinger, R., Mildenberger, S., Troppmair, J., and Gekle, M. (2002). Human epidermal growth factor receptor-1 expression renders Chinese hamster ovary cells sensitive to alternative aldosterone signaling. J Biol Chem 277, 45892-45897.
14. Livak, K. J., and Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
15. Mattoon, D. R., Lamothe, B., Lax, I., and Schlessinger, J. (2004). The docking protein Gab1 is the primary mediator of EGF-stimulated activation of the PI-3K/Akt cell survival pathway. BMC Biol 2, 24.
16. Narayan, M., Wilken, J. A., Harris, L. N., Baron, A. T., Kimbler, K. D., and Maihle, N. J. (2009). Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 69, 2191-2194.
17. Rothe, M., Treder, M., Hartmann, S., Freeman, D., and Radinsky, B. (2007). Antibodies directed to HER-3 and uses thereof. In World Intellectual Property Organization, W. I. P. Organization, ed.
18. Schoeberl, B., Pace, E. A., Fitzgerald, J. B., Harms, B. D., Xu, L., Nie, L., Linggi, B., Kalra, A., Paragas, V., Bukhalid, R., et al. (2009). Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2, ra31.
19. Shepard, H. M., Brdlik, C., and Schreiber, H. (2008). Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. The Journal of Clinical Investigation 118, 3574-3581.
20. Sierke, S. L., Cheng, K., Kim, H. H., and Koland, J. G. (1997). Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 322(Pt 3), 757-763.
21. Suenaga, A., Takada, N., Hatakeyama, M., Ichikawa, M., Yu, X., Tomii, K., Okimoto, N., Futatsugi, N., Narumi, T., Shirouzu, M., et al. (2005). Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-kinase and ErbB3 receptor-derived phosphotyrosyl peptides. J Biol Chem 280, 1321-1326.
22. Wheeler, D. L., Huang, S., Kruser, T. J., Nechrebecki, M. M., Armstrong, E. A., Benavente, S., Gondi, V., Hsu, K. T., and Harari, P. M. (2008). Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27, 3944-3956.
23. Zhang, N., Liu, L., Dan Dumitru, C., Cummings, N. R., Cukan, M., Jiang, Y., Li, Y., Li, F., Mitchell, T., Mallem, M. R., et al. (2011). Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 3, 298-98.